4/A: Citius Oncology Director Granted 300,000 Restricted Stock Units

Citius Oncology, Inc. director Suren G. Dutia was granted 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Summary

• Suren G. Dutia, a Director of Citius Oncology, Inc. (CTOR), was granted 300,000 restricted stock units (RSUs).
• The grant date for these RSUs was September 19, 2025.
• The shares underlying these RSUs will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Mr. Dutia's continuous service to Citius Oncology, Inc. or a related entity.
• The transaction was reported on an amended Form 4, with the original filed on September 23, 2025, and the amendment signed on December 22, 2025.

Sentiment

Score: 6

Explanation: The filing reports a standard equity compensation event for a director, which is generally a neutral to slightly positive signal as it aligns interests. There are no negative financial or operational disclosures.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages retention of key management personnel over a three-year period.

Risks

• The value of the RSUs is tied to the future performance of Citius Oncology, Inc.'s common stock, which could fluctuate.
• The vesting is subject to continuous service, meaning the director must remain with the company for the shares to fully vest.

Future Outlook

The restricted stock units are designed to vest on the third anniversary of the grant date, contingent on the reporting person's continuous service, indicating a long-term incentive structure for the director.

Management Comments

• Represents restricted stock units granted on September 19, 2025.
• The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. or a Related Entity.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and pharmaceutical industry, used to align executive and director incentives with long-term company performance and shareholder interests. This type of equity compensation is a standard component of remuneration packages for board members in growth-oriented companies like Citius Oncology.

Comparison to Industry Standards

• The three-year cliff vesting schedule for restricted stock units is a common practice for director compensation in the biotech sector, similar to companies like Moderna or BioNTech, which often use multi-year vesting to ensure long-term commitment.
• The grant of 300,000 units, while specific to Citius Oncology's compensation philosophy, is within the typical range for non-employee director equity grants in small to mid-cap biopharmaceutical companies, often benchmarked against peer groups.

Stakeholder Impact

• Shareholders: The grant of RSUs dilutes existing shareholder ownership slightly upon vesting but aims to align director incentives with long-term shareholder value creation.
• Employees: No direct impact on general employees is noted, but it reflects the company's compensation strategy for leadership.

Next Steps

• The restricted stock units will vest on September 19, 2028, assuming continuous service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Citius Oncology. It's a standard event for aligning director incentives with long-term company performance. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not provide new catalysts for a 'buy' or 'sell' decision.

Keywords

Citius Oncology, CTOR, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Beneficial Ownership, Form 4